Skip to main content

Genzyme Diagnostics Forgoes Access to Future Syn-X Technologies in Effort to Resolve Dispute

NEW YORK, July 11 – Genzyme Diagnostics no longer has first offer rights to future technologies developed by Syn-X Pharma, following an agreement that resolves previous disputes between the two companies.

In a statement issued on Tuesday, Genzyme and Syn-X announced that Genzyme would continue to develop a stroke panel called NeuroTrak, while Syn-X would retain rights to future royalty payments based on product sales.

Genzyme, however, is no longer obligated to make financial obligations to Syn-X and no longer has special rights to the Canadian proteomics company’s technology.

"The new agreement is a win-win situation," Sean McNicholas, CEO of SYN-X, said in a statement. "It allows Genzyme to continue to develop the stroke technology and SYN-X the opportunity to focus on accelerating the development of our pipeline products." 

Genzyme Diagnostics said it expected to complete clinical trials of the new stroke panel in 2003.

Genzyme Diagnostics of Cambridge, Mass., is a business unit of Genzyme General. Syn-X is based in Mississauga, Ontario. It has developed the Proteomics Discovery Platform, a technology that can be used to identify drug targets as well as to develop specialized antibody-based diagnostics. 

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.